Par Drugs board approved audited standalone financial results for Q4 and FY26 ended March 31, 2026, with an unmodified audit opinion.
SEBI has restrained the company's proposed business transfer arrangement, creating a key audit matter for going concern assessment.
The board authorized investments up to ₹90 crore and noted payment of ₹25.14 lakh bonus to employees for FY26.
Other approvals included sale of motor vehicle for ₹1.50 lakh and renewal of banking facility with Kotak Mahindra Bank.